Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTDZN01)

• DTT Name: Cathepsin K (CTSK) DTT Info
• Gene Name: CTSK

Molecule-Related Drug & Molecule List

3 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Odanacatib	DM1EO3G	Osteoporosis	FB83.0	Phase 3	[1]
SAR-114137	DMZ1XR5	Pain	MG30-MG3Z	Phase 1	[2]
VEL-0230	DMDSC63	Rheumatoid arthritis	FA20	Phase 1	[3]

8 Patented Agent(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Oxotetrahydro-2-H-furo[3.2-b]pyrrol-4(5-H)-yl derivative 1	DM1SH5R	Pain	MG30-MG3Z	Patented	[4]
PMID25399719-Compound-17	DMRXKJZ	N. A.	N. A.	Patented	[5]
PMID27998201-Compound-10	DMVXTIL	Osteoporosis	FB83.0	Patented	[4]
PMID27998201-Compound-12	DM8QZNC	Bone cancer	2B5Z	Patented	[4]
PMID27998201-Compound-15	DMOB8LU	Pain	MG30-MG3Z	Patented	[4]
PMID27998201-Compound-5	DMVZ0ND	Chronic obstructive pulmonary disease	CA22	Patented	[4]
PMID27998201-Compound-8	DMZK0SY	N. A.	N. A.	Patented	[4]
PMID27998201-Compound-9	DM1JOZN	Rheumatoid arthritis	FA20	Patented	[4]

4 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Balicatib	DM06JTL	Osteoporosis	FB83.0	Discontinued in Phase 2	[6]
ONO-5334	DMWS7C2	Osteoporosis	FB83.0	Discontinued in Phase 2	[7]
Relacatib	DMLJEFH	Bone metastases	2D50	Discontinued in Phase 2	[8]
MIV-701	DM23KBM	Osteoporosis	FB83.0	Discontinued in Phase 1	[9]

2 Preclinical Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
GW-2592X	DMNAT5V	Osteoporosis	FB83.0	Preclinical	[10]
L-006235-1	DMMEH12	Osteoarthritis	FA00-FA05	Preclinical	[11]

48 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
(S)-1-benzylcyclopentyl 1-oxohexan-2-ylcarbamate	DMICUQK	Discovery agent	N.A.	Investigative	[12]
(S)-tert-butyl 1-oxohexan-2-ylcarbamate	DMAQX4K	Discovery agent	N.A.	Investigative	[12]
(S)-tert-butyl 4-methyl-1-oxopentan-2-ylcarbamate	DMR1HQ3	Discovery agent	N.A.	Investigative	[12]
2-cyclohexylamino-pyridine-2-carbonitrile	DMFMZRB	Discovery agent	N.A.	Investigative	[13]
2-cyclohexylamino-pyrimidine-4-carbonitrile	DMMIGXO	Discovery agent	N.A.	Investigative	[13]
3-Amino-5-Phenylpentane	DMHDFZE	Discovery agent	N.A.	Investigative	[14]
4-cycloheptyl-6-propylpyrimidine-2-carbonitrile	DMNT5BF	Discovery agent	N.A.	Investigative	[15]
4-cyclohexyl-6-propylpyrimidine-2-carbonitrile	DM10U6S	Discovery agent	N.A.	Investigative	[15]
4-cyclohexylamino-pyrimidine-2-carbonitrile	DMGVIXW	Discovery agent	N.A.	Investigative	[13]
4-cyclooctyl-6-propylpyrimidine-2-carbonitrile	DMS42TN	Discovery agent	N.A.	Investigative	[15]
4-phenyl-6-propylpyrimidine-2-carbonitrile	DMMIB0R	Discovery agent	N.A.	Investigative	[16]
4-propyl-6-m-tolylpyrimidine-2-carbonitrile	DMNM4GE	Discovery agent	N.A.	Investigative	[16]
AM-3701	DMZVLJH	Bone metastases	2D50	Investigative	[10]
BF/PC-21	DMCWB1V	Inflammation	1A00-CA43.1	Investigative	[10]
Boc-Agly-Val-Agly-OEt	DMDX8M3	Discovery agent	N.A.	Investigative	[17]
GNF-PF-5434	DMP9AIH	Discovery agent	N.A.	Investigative	[18]
L-873724	DMUP516	Asthma	CA23	Investigative	[8]
MIV-710	DM13TUY	Bone metastases	2D50	Investigative	[10]
N-(1-((cyanomethyl)carbamoyl)cyclohexyl)benzamide	DMBQ5NS	Discovery agent	N.A.	Investigative	[19]
N-(4-phenylbenzoyl)-phenylalanyl-glycine-nitrile	DMUJS4Y	Discovery agent	N.A.	Investigative	[20]
N-(benzyloxycarbonyl)-leucyl-glycine-nitrile	DMR18YI	Discovery agent	N.A.	Investigative	[20]
N-(cyanomethyl)cyclohex-1-ene-1-carboxamide	DMTKREZ	Discovery agent	N.A.	Investigative	[19]
N-(tert-butoxycarbonyl)-isoleucyl-glycine-nitrile	DMJ0S5C	Discovery agent	N.A.	Investigative	[20]
N-(tert-butoxycarbonyl)-leucyl-glycine-nitrile	DMXYQWG	Discovery agent	N.A.	Investigative	[20]
N-(tert-butoxycarbonyl)-methionyl-glycine-nitrile	DM3I0WZ	Discovery agent	N.A.	Investigative	[20]
N-(tert-butoxycarbonyl)-norleucyl-glycine-nitrile	DMGF4XC	Discovery agent	N.A.	Investigative	[20]
N-(tert-butoxycarbonyl)-norvalyl-glycine-nitrile	DMOP5N7	Discovery agent	N.A.	Investigative	[20]
N-(tert-butoxycarbonyl)-valyl-glycine-nitrile	DMUQBOP	Discovery agent	N.A.	Investigative	[20]
N-acetyl-phenylalanyl-glycine-nitrile	DME8O69	Discovery agent	N.A.	Investigative	[20]
N-benzoyl-phenylalanyl-glycine-nitrile	DMRJ4B1	Discovery agent	N.A.	Investigative	[20]
P2,P3 Ketoamide derivative	DMETL3Z	Discovery agent	N.A.	Investigative	[21]
PMID16290936C1b	DMOP8YM	Discovery agent	N.A.	Investigative	[12]
Pyrrolidine-1-carbonitrile	DM906JK	Discovery agent	N.A.	Investigative	[22]
Tert-butyl (2S)-1-cyanopyrrolidine-2-carboxylate	DM8LI1K	Discovery agent	N.A.	Investigative	[22]
TERT-BUTYL 2-CYANO-2-METHYLHYDRAZINECARBOXYLATE	DMZG5I7	Discovery agent	N.A.	Investigative	[23]
Tert-Butyl(1s)-1-Cyclohexyl-2-Oxoethylcarbamate	DM42WFH	Discovery agent	N.A.	Investigative	[23]
Z-Ala-Leu-His-Agly-Ile-Val-OMe	DMMP0DT	Discovery agent	N.A.	Investigative	[17]
Z-Ala-Leu-lle-Agly-Ile-Val-NHBzl	DM7IGRT	Discovery agent	N.A.	Investigative	[17]
Z-Ala-Leu-lle-Agly-Ile-Val-OMe	DMVEUOL	Discovery agent	N.A.	Investigative	[17]
Z-Ala-Leu-Nal-Agly-Ile-Val-OMe	DM3209T	Discovery agent	N.A.	Investigative	[17]
Z-Ala-Leu-Phe-Agly-Ile-Val-OMe	DML16BT	Discovery agent	N.A.	Investigative	[17]
Z-Ala-Leu-Tyr(Me)-Agly-Ile-Val-OMe	DMIB5O3	Discovery agent	N.A.	Investigative	[17]
Z-Arg-Leu-Val-Agly-Ala-Gly-NH2	DM69FKN	Discovery agent	N.A.	Investigative	[17]
Z-Arg-Leu-Val-Agly-Ile-Val-Trp-NH2	DMZDGJO	Discovery agent	N.A.	Investigative	[17]
Z-Arg-Leu-Val-Agly-Ileu-Val-OMe	DMT0UZ1	Discovery agent	N.A.	Investigative	[17]
Z-Arg-Leu-Val-Agly-Trp-Val-Ala-NH2	DMM5O2V	Discovery agent	N.A.	Investigative	[17]
Z-Arg-Leu-Val-Agly-Val-Ala-NH2	DMTWNH7	Discovery agent	N.A.	Investigative	[17]
Z-leu-Val-Agly-Val-OBzl	DM6OGR9	Discovery agent	N.A.	Investigative	[17]

References

• [1] A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8.
• [2] From laboratory to pilot plant: the solid-state process development of a highly potent cathepsin S/K inhibitor. Eur J Pharm Biopharm. 2013 Apr;83(3):436-48.
• [3] Discovery and parallel synthesis of a new class of cathepsin K inhibitors. Bioorg Med Chem Lett. 2001 Nov 19;11(22):2951-4.
• [4] Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656.
• [5] An updated patent review of calpain inhibitors (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):17-31.
• [6] Current and future treatments of bone metastases. Expert Opin Emerg Drugs. 2008 Dec;13(4):609-27.
• [7] New approach for osteoporosis treatment: cathepsin K inhibitor, ONO-5334. Clin Calcium. 2011 Jan;21(1):64-9.
• [8] The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. Bioorg Med Chem Lett. 2008 Feb 1;18(3):923-8.
• [9] Medivir designates MIV-710 a Candidate Drug (CD) for Osteoporosis and Osteoarthritis, 2009
• [10] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2350).
• [11] Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional se... J Med Chem. 2005 Dec 1;48(24):7535-43.
• [12] Semicarbazone-based inhibitors of cathepsin K, are they prodrugs for aldehyde inhibitors Bioorg Med Chem Lett. 2006 Feb 15;16(4):978-83.
• [13] 2-Cyano-pyrimidines: a new chemotype for inhibitors of the cysteine protease cathepsin K. J Med Chem. 2007 Feb 22;50(4):591-4.
• [14] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [15] Design and optimization of a series of novel 2-cyano-pyrimidines as cathepsin K inhibitors. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1524-7.
• [16] 2-Phenyl-9H-purine-6-carbonitrile derivatives as selective cathepsin S inhibitors. Bioorg Med Chem Lett. 2010 Aug 1;20(15):4447-50.
• [17] Azapeptides structurally based upon inhibitory sites of cystatins as potent and selective inhibitors of cysteine proteases. J Med Chem. 2002 Sep 12;45(19):4202-11.
• [18] Substrate optimization for monitoring cathepsin C activity in live cells. Bioorg Med Chem. 2009 Feb 1;17(3):1064-70.
• [19] Beta-substituted cyclohexanecarboxamide: a nonpeptidic framework for the design of potent inhibitors of cathepsin K. J Med Chem. 2006 Feb 9;49(3):1066-79.
• [20] Interaction of papain-like cysteine proteases with dipeptide-derived nitriles. J Med Chem. 2005 Dec 1;48(24):7688-707.
• [21] Potent and selective P2-P3 ketoamide inhibitors of cathepsin K with good pharmacokinetic properties via favorable P1', P1, and/or P3 substitutions. Bioorg Med Chem Lett. 2004 Oct 4;14(19):4897-902.
• [22] Acyclic cyanamide-based inhibitors of cathepsin K. Bioorg Med Chem Lett. 2005 Jun 15;15(12):3039-43.
• [23] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.